| 7.03 0.26 (3.84%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.52 | 1-year : | 9.95 |
| Resists | First : | 7.3 | Second : | 8.52 |
| Pivot price | 6.79 |
|||
| Supports | First : | 6.5 | Second : | 6.01 |
| MAs | MA(5) : | 6.81 |
MA(20) : | 6.72 |
| MA(100) : | 7.41  |
MA(250) : | 9.72 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.9 |
D(3) : | 43.6 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 15.96 | Low : | 6.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANGO ] has closed below upper band by 2.0%. Bollinger Bands are 57.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.89 - 6.93 | 6.93 - 6.96 |
| Low: | 6.51 - 6.56 | 6.56 - 6.6 |
| Close: | 6.7 - 6.77 | 6.77 - 6.84 |
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Thu, 07 Dec 2023
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024 - Business Wire
Mon, 04 Dec 2023
AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Tue, 28 Nov 2023
AngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You Trade - Zacks Investment Research
Tue, 21 Nov 2023
Angiodynamics Inc. ($ANGO) Trading Report - Stock Traders Daily
Thu, 16 Nov 2023
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Thu, 12 Oct 2023
AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Instruments & Supplies
|
|
| Shares Out | 40 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 88.8 (%) |
| Shares Short | 1,450 (K) |
| Shares Short P.Month | 928 (K) |
| EPS | 0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.64 |
| Profit Margin | 1.9 % |
| Operating Margin | -12.4 % |
| Return on Assets (ttm) | -2.5 % |
| Return on Equity (ttm) | 1.5 % |
| Qtrly Rev. Growth | -3.5 % |
| Gross Profit (p.s.) | 4.37 |
| Sales Per Share | 8.42 |
| EBITDA (p.s.) | 0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 25 (M) |
| PE Ratio | 46.86 |
| PEG Ratio | -1.4 |
| Price to Book value | 0.66 |
| Price to Sales | 0.83 |
| Price to Cash Flow | -259.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|